Kaposi Sarcoma in case of solid organ transplantation

Kaposi sarcoma (KS) is a soft tissue cancer that is related to several intrinsic and environ­mental factors. In the general population, KS is an extremely rare tumor, however, the risk of its development is substantially increased in immune compromised patients including patients with acquired immune deficiency syndrome (AIDS) and solid organ recipients. Genetic predisposition, seropositivity for human herpes virus type HHV, and increased HHV prevalence in the general population are some proposed factors for the development of KS. Middle East is reported as a highly prevalent region for the incidence of post-transplant KS, reports from Saudi Arabia, Egypt and Turkey indicate a high incidence of this disease. Kaposi sarcoma was first described by Moritz Kaposi in the 1870, the disease was a medical curiosity in Europe and the United States until the acquired immunodeficiency syndrome was recognized in 1981.

 

    Related Conference of Kaposi Sarcoma in case of solid organ transplantation

    November 21-22, 2024

    11th World Congress on Epigenetics and Chromosome

    Dubai, UAE
    December 09-10, 2024

    17th World Congress on Stem Cell Research

    Dubai, UAE
    March 17-18, 2025

    8th Global Conference on Cell and Gene Therapy

    Paris, France
    June 16-17, 2025

    21st Global Summit on Stem Cell & Regenerative Medicine

    Frankfurt, Germany

    Kaposi Sarcoma in case of solid organ transplantation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in